Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 January 2019 | Story Charlene Stanley | Photo Charlene Stanley
Michele Middle
Michelle Middle, CMO of Farmovs, looks forward to expanding their operations after the UFS acquired 100% shareholding in 2018.

In medical research, there are NO shortcuts.

The journey of a new medicine from lab to pharmacy shelf takes on average at least 10 years.

Michelle Middle’s journey from young medical graduate starting her first job at FARMOVS to becoming the company’s Chief Medical Officer, was more than twice that long. It was a journey that systematically and adequately equipped her to now Co-captain this flagship enterprise through its biggest challenge yet.

Michelle remembers how Farmovs started in 1974 as a research centre in the Department of Pharmacology. After graduating as medical doctor, she joined Farmovs in 1993, shortly before they moved to their current extensive facilities just south of the Sasol Library.

In 2000, international Clinical Research Organization (CRO) giant Parexel acquired a 70% shareholding, and the name changed to Farmovs-Parexel.

“Parexel really invested a lot in infrastructure and technology, bringing facilities here on par with the best in the world,” says Michelle.

Her own journey in medical research took her to George and later to the US and UK, where she held various international executive leadership positions in international companies.

When the UFS acquired a 100% shareholding in Farmovs earlier this year, she came full circle, as she returned to Bloemfontein to spearhead the expansion of patient studies in collaboration with the Faculty of Health Sciences.

“The opportunities we have here are really enormous,” says an excited Michelle.

“We are the only university in the country with this kind of infrastructure. Apart from our state-of-the-art bioanalytical lab, we also have facilities to accommodate close to 100 research participants. We now have 45 years’ experience in advanced medical research, plus established international clients. We can provide pharmaceutical companies with basically everything they need to develop new medicines.”

Another exciting development is that they are expanding their clinical-trial patient population next year from healthy individuals to people suffering from a host of chronic conditions.

“While they are part of our clinical trials, patients gain valuable insight in their own conditions. We also sometimes pick up underlying medical issues they were not even aware of,” says Michelle.

The 150 Farmovs staff members range from doctors and nurses, to technologists, medical writers, and managers. While not technically part of the university staff, they form a valued part of the Bloemfontein Campus community.

News Archive

UFS lecturer overcomes barriers to become world-class researcher
2016-09-05

Description: Dr Magteld Smith researcher and deaf awareness activist Tags: Dr Magteld Smith researcher and deaf awareness activist

Dr Magteld Smith researcher and deaf awareness
activist, from the Department of Otorhinolaryngology
at the UFS.
Photo: Nonsindiso Qwabe

Renowned author and disability activist Helen Keller once said the problems that come with being deaf are deeper and more far-reaching than any other physical disability, as it means the loss of the human body’s most vital organ, sound.

Dr Magteld Smith, researcher at the Department of Otorhinolaryngology (Ear, Nose and Throat) at the University of the Free State, said hearing loss of any degree can have psychological and sociological implications which may impair the day-to-day functioning of an individual, as well as preventing the person from reaching full potential. That is why Smith is making it her mission to bring about change in the stigmatisation surrounding deafness.

Beating the odds
Smith was born with bilateral (both ears) severe hearing loss, which escalated to profound deafness. But she has never allowed it to hinder her quality of life. She matriculated from a school for the deaf in 1985. In 2008 she received a cochlear implant   a device that replaces the functioning of the damaged inner ear by providing a sense of sound to the deaf person   which she believes transformed her life. Today, she is the first deaf South African to possess two masters degrees and a PhD.

She is able to communicate using spoken language in combination with her cochlear implant, lip-reading and facial expressions. She is also the first and only deaf person in the world to have beaten the odds to become an expert researcher in various fields of deafness and hearing loss, working in an Otorhinolaryngology department.

Advocating for a greater quality of life
An advocate for persons with deafness, Smith conducted research together with other experts around the world which illustrated that cochlear implantation and deaf education were cost-effective in Sub-Saharan Africa. The cost-effectiveness of paediatric cochlear implantation has been well-established in developed countries; but is unknown in low resource settings.

However, with severe-to-profound hearing loss five times higher in low and middle-income countries, the research emphasises the need for the development of cost-effective management strategies in these settings.

This research is one of a kind in that it states the quality of life and academic achievements people born with deafness have when they use spoken language and sign language as a mode of communication is far greater than those who only use sign language without any lip-reading.

Deafness is not the end

What drives Smith is the knowledge that deaf culture is broad and wide. People with disabilities have their own talents and skills. All they need is the support to steer them in the right direction. She believes that with the technological advancements that have been made in the world, deaf people also have what it takes to be self-sufficient world-changers and make a lasting contribution to humanity.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept